SS-31

Overview

SS-31, also known as elamipretide or MTP-131, is a small synthetic tetrapeptide designed to target mitochondria, the energy-producing structures within cells. Its distinguishing feature is an affinity for cardiolipin, a lipid found in the inner mitochondrial membrane that is essential for efficient energy production. By concentrating at this membrane, SS-31 aims to stabilize mitochondrial function and reduce the cellular damage that occurs when energy machinery falters.

This focus on mitochondrial health has made SS-31 a candidate for a range of conditions in which impaired cellular energy is thought to play a role. These include primary mitochondrial myopathies, heart failure, and certain eye diseases such as dry age-related macular degeneration. The underlying idea is that protecting mitochondria could slow or reverse dysfunction across diverse tissues that depend heavily on energy.

SS-31 is an investigational compound that has undergone meaningful clinical testing, but it is not an approved therapy. Its trial history has produced mixed results, with some studies suggesting benefit and others failing to meet their primary goals. This combination of a compelling mechanism and inconsistent clinical outcomes makes SS-31 a closely watched but still unproven agent in mitochondrial medicine.

How it works

SS-31 is part of a family of cell-permeable peptides engineered to accumulate within mitochondria. Once there, it binds selectively to cardiolipin, a phospholipid concentrated in the inner mitochondrial membrane. Cardiolipin organizes the proteins of the electron transport chain, the system responsible for generating cellular energy. When cardiolipin is disrupted, energy production becomes inefficient and harmful reactive oxygen species are generated.

By associating with cardiolipin, SS-31 is proposed to help preserve the structure and function of the inner membrane, supporting more efficient energy production and reducing oxidative stress. This is thought to protect cells from the cascade of damage that follows mitochondrial dysfunction, including membrane breakdown and cell death. Tissues with high energy demands, such as heart muscle, skeletal muscle, and retinal cells, are considered the most likely to benefit.

This mechanism is biologically attractive because mitochondrial dysfunction is implicated in many chronic and age-related diseases. However, stabilizing mitochondria at the molecular level does not automatically guarantee improvement in whole-organ function or in patient symptoms. The gap between a sound cellular mechanism and reliable clinical benefit is precisely where SS-31's development has encountered difficulty, underscoring that mechanistic plausibility alone is not proof of effectiveness.

Research & evidence

SS-31, as elamipretide, has been studied across several clinical programs, giving it a more substantial human research record than many experimental peptides. Investigations have included primary mitochondrial myopathy, where patients suffer muscle weakness due to defective mitochondria, as well as heart failure and ophthalmic conditions such as dry age-related macular degeneration. These trials reflect the broad set of tissues in which mitochondrial dysfunction is thought to matter.

The results have been genuinely mixed. Some studies have reported encouraging signals on secondary measures or in subgroups, while several key trials did not meet their primary endpoints. In mitochondrial myopathy, for example, outcomes have been inconsistent across different study designs. This pattern of partial or unconfirmed benefit has complicated the compound's path toward approval and tempered early optimism.

The honest interpretation is that SS-31 remains an investigational agent whose clinical efficacy has not been clearly established. The biology is compelling and the trials have been serious and well-resourced, yet the data have not delivered the consistent, robust benefit that regulatory approval requires. Ongoing analysis continues to explore which conditions, patient populations, or endpoints might respond, but at present no indication has been definitively proven.

Safety & legal status

Across its clinical trials, elamipretide has generally been described as reasonably tolerated, with much of the safety information coming from supervised study settings. Injection-related reactions have been among the more commonly noted effects. However, because the compound is still investigational, the complete long-term safety picture, including effects of extended use, is not fully defined, and conclusions remain dependent on the trial data gathered so far.

Because SS-31 is an experimental drug, appropriate use is confined to clinical research conducted under medical supervision. Peptide material marketed online outside of these channels cannot be assumed to match pharmaceutical quality, and concerns about purity, accurate dosing, and contamination apply. These quality issues represent risks separate from the molecule's own properties and are a recurring problem with unregulated peptides.

In terms of regulatory status, SS-31 is not an approved medication. It has not received marketing authorization for mitochondrial myopathy, heart failure, macular degeneration, or any other condition, and it is not a dietary supplement. It is not legally marketed for general consumer use. The accurate framing is that SS-31 is an investigational therapeutic under continued evaluation rather than an available or proven treatment.

Frequently asked questions

References

Each source links to its original record — peer-reviewed studies, regulator pages, or reference texts, labelled by type. We summarize findings neutrally; a citation is a reference, not an endorsement, and not a claim that its authors reviewed this page.

1. Karaa A, Haas R, Goldstein A, et al. Randomized dose-escalation trial of elamipretide in adults with primary mitochondrial myopathy. Neurology. 2018. Peer-reviewed study
2. Szeto HH. First-in-class cardiolipin-protective compound as a therapeutic agent to restore mitochondrial bioenergetics. Br J Pharmacol. 2014. Peer-reviewed study
3. Zhao W, Xu Z, Cao J, et al. Elamipretide (SS-31) improves mitochondrial dysfunction, synaptic and memory impairment induced by lipopolysaccharide in mice. J Neuroinflammation. 2019. Peer-reviewed study
4. Zheng H, Ou J, Han H, et al. SS-31@Fer-1 Alleviates ferroptosis in hypoxia/reoxygenation cardiomyocytes via mitochondrial targeting. Biomed Pharmacother. 2025. Peer-reviewed study
5. Nie Y, Li J, Zhai X, et al. Elamipretide(SS-31) Attenuates Idiopathic Pulmonary Fibrosis by Inhibiting the Nrf2-Dependent NLRP3 Inflammasome in Macrophages. Antioxidants (Basel). 2023. Peer-reviewed study
6. Whitson JA, Martín-Pérez M, Zhang T, et al. Elamipretide (SS-31) treatment attenuates age-associated post-translational modifications of heart proteins. Geroscience. 2021. Peer-reviewed study